Lanadelumab-Flyo

TAKHZYRO

Plasma Kallikrein Inhibitor

NADAC/unit N/A

No Shortage Tier 1: 0.9% PA Req: 25.5%

TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older.

Covered Lives

Explore in the Ecosystem

rxsaver.aiCompare prices for Lanadelumab-Flyo drfinder.aiFind doctors who prescribe Lanadelumab-Flyo rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Lanadelumab-Flyo

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.